Compare CRTO & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRTO | TBPH |
|---|---|---|
| Founded | 2005 | 2013 |
| Country | France | United States |
| Employees | 3649 | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 780.6M | 824.9M |
| IPO Year | 2013 | 2013 |
| Metric | CRTO | TBPH |
|---|---|---|
| Price | $16.41 | $16.99 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 6 |
| Target Price | ★ $34.00 | $18.40 |
| AVG Volume (30 Days) | 235.3K | ★ 304.2K |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 38.95 | ★ 279.13 |
| EPS | 0.15 | ★ 2.06 |
| Revenue | ★ $2,296,692,000.00 | $15,386,000.00 |
| Revenue This Year | N/A | $8.46 |
| Revenue Next Year | $5.54 | N/A |
| P/E Ratio | ★ $5.92 | $8.25 |
| Revenue Growth | ★ 27.65 | N/A |
| 52 Week Low | $15.58 | $8.33 |
| 52 Week High | $28.91 | $21.03 |
| Indicator | CRTO | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 37.25 | 59.89 |
| Support Level | N/A | $16.14 |
| Resistance Level | $20.10 | $17.24 |
| Average True Range (ATR) | 0.90 | 0.40 |
| MACD | -0.31 | 0.01 |
| Stochastic Oscillator | 18.63 | 86.47 |
Criteo SA is an ad-tech company in the digital advertising market. Its technology allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. Retail Media: This segment encompasses revenue generated from brands, agencies, and retailers for the purchase and sale of retail media digital advertising inventory and audiences, and services. Performance Media: This segment encompasses targeting capabilities and supply and AdTech services. The majority of its revenues is generated from the performance media segment.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.